December 18, 2024
In this PharmaPhorum byline, Pleio’s Chief Experience Officer Abby Reynolds explores how pharmaceutical companies can better support patients using GLP-1s by addressing the emotional barriers to weight loss. From stigma and social isolation to misinformation and adherence challenges, Reynolds makes the case for human-first, personalized patient support programs that foster connection, resilience, and real-world success with GLP-1 therapy.
December 12, 2024
“Peer-to-patient platforms use the benefits of human-first support with the power of technology to inform and enhance human interactions. For example, use of conversational analysis and conversational intelligence—powered by the latest in AI technology—helps us both understand the structure of conversation and promote effective and empathic communication with patients. Still, I see the greatest opportunity in utilizing AI to improve human interactions, not replace them.” – Abby Reynolds, Chief Experience Officer at Pleio
November 20, 2024
“Digital health plays a major role in shaping, extending and facilitating human connections. This patient-centered approach will lead to better outcomes, where adherence is driven not by obligation but by a genuine partnership in the patient’s health journey.” – Michael Oleksiw, Chief Executive Officer at Pleio